BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 24607278)

  • 21. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
    Tesoriero AA; Wong EM; Jenkins MA; Hopper JL; Brown MA; Chenevix-Trench G; Spurdle AB; Southey MC;
    Hum Mutat; 2005 Nov; 26(5):495. PubMed ID: 16211554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
    J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
    Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
    Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
    Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
    PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
    Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
    BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of common BRCA1 and BRCA2 variants.
    Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
    Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
    J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
    Cifuentes-C L; Rivera-Herrera AL; Barreto G
    Colomb Med (Cali); 2019 Sep; 50(3):163-175. PubMed ID: 32284662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
    Ramus SJ; Harrington PA; Pye C; DiCioccio RA; Cox MJ; Garlinghouse-Jones K; Oakley-Girvan I; Jacobs IJ; Hardy RM; Whittemore AS; Ponder BA; Piver MS; Pharoah PD; Gayther SA
    Hum Mutat; 2007 Dec; 28(12):1207-15. PubMed ID: 17688236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.
    Nakagomi H; Mochizuki H; Inoue M; Hirotsu Y; Amemiya K; Sakamoto I; Nakagomi S; Kubota T; Omata M
    Cancer Sci; 2018 Feb; 109(2):453-461. PubMed ID: 29215753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.